CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Argos Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Argos Therapeutics, Inc.
4233 Technology Drive
Phone: (919) 287-6300p:919 287-6300 Durham, NC  27704-2173  United States Fax: (302) 636-5454f:302 636-5454
This company is no longer actively traded on any major stock exchange.
Business Summary
Argos Therapeutics, Inc., also known as Merix Bioscience, Inc., is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201812/31/2017YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Vice President - Finance Lori R.Harrelson 45 7/1/2011 2/24/2010
Vice President - Corporate Communications & Investor Relations John D.Menditto 6/15/2015 6/15/2015
Vice President - Medical and Clinical Affairs Douglas C.Plessinger 46 10/1/2011 10/1/2011
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Argos Therapeutics (Europe) S.à.r.l
ARGS
ARGSQ
DC Bio Corp.
Merlx Bioscience, Inc.

General Information
Number of Employees: 39 (As of 2/28/2018)
Outstanding Shares: 10,586,661 (As of 11/17/2018)
Shareholders: 50
Stock Exchange: OTC
Federal Tax Id: 562110007
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023